IF: 0.644
REUTERS THOMSON

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C

AUTHORS

Mostafa Alavi Moghaddam 1 , Mohammad Reza Zali 1 , Seyed Hossein Aalaei-Andabili 2 , * , Faramarz Derakhshan 1 , SM Miri 2 , Seyed Alavian 2

AUTHORS INFORMATION

1 Research Institute of Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

2 Baqiyatallah University of Medical Sciences, Baqiyatallah Research Center for Gastroenterology and Liver Disease (BRCGL), Tehran, IR Iran

How to Cite: Alavi Moghaddam M, Zali M R, Aalaei-Andabili S H, Derakhshan F, Miri S, et al. High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C, Iran Red Crescent Med J. 2012 ; 14(8):e95955.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 14 (8); e95955
Published Online: August 31, 2012
Article Type: Research Article
Received: July 03, 2019
Accepted: August 31, 2012

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Hepatitis C is a major reason of morbidity and mortality among hemophilia patients. Although combi­nation therapy with peginterferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed.
Objectives: In this study, efficacy and tolerability of combination therapy with peginterferon α-2a–ribavirin was inves­tigated among hemophilia HCV infected patients.
Patients and Materials: In a quasi-experimental, 45 naive hemophilia patients with chronic HCV received 180 mg of pegylated interferon (Pegasys) by subcutaneous injection weekly plus an oral dose of 800-1200 μg ribavirin daily ac­cording to body weight. The treatment continued 48 weeks in patients with genotype one and 24 weeks in those with genotype 3. Sustained virological response (SVR) was considered as efficacy of treatment.
Result: Forty three patients (95.6%) reached to end of treatment response (ETR); only two (4.4%) patients did not re­spond and were discontinued from treatment. None of 43 patients relapsed. SVR obtained in 43 of 45 patients (95.6%), in multivariate logistic regression model, third month’s treatment WBC (WBC > 2000) remained the only significant predictor of SVR. Regimen dose reduced in three patients; two of those because of ALT increasing and other one for his retinal bleeding. In repeated measurement analysis, alanine aminotransferase (ALT) and hemoglobin (Hb) decreased significantly during treatment, but reduction of platelet (PLT) was not significant.
Conclusions: Results show high efficacy and safety of combination therapy of Peg-IFN-α 2a plus ribavirin among he­mophiliacs with chronic hepatitis C.

Keywords

Hepatitis C Hemophilia A Hemophilia B Peginterferon alfa-2a Ribavirin Iran

© 2012, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

This part is available in the PDF file.

References

  • 1. The references are available in the PDF file.
  • COMMENTS

    LEAVE A COMMENT HERE: